- Entry
- $3.42
- Final
- $2.60 -24.0%
- Target
- —
- Score
- -1.00
ImmunityBio (IBRX) just received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cancer immunotherapy, ANKTIVA, which targets bladder cancer. This designation is a strong signal that the treatment has significant potential and allows for an expedited regulatory pathway, potentially leading to faster approval and commercialization. If ANKTIVA continues to show strong results in trials, it could lead to sustained growth, a higher valuation, and possibly even partnerships or acquisition interest from larger pharmaceutical companies. IBRX pumped 25% …
— ORIGINAL POST ·
IBRX – FDA RMAT Designation Could Be a Huge Catalyst
· r/wallstreetbets
· Feb 28, 2025